AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Poolbeg Pharma PLC
Video analysis: POLBF
All videosNo video analysis for this stock yet. Request one from our team.
News: POLBF
Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug
Poolbeg Pharma PLC (AIM:POLB) has secured a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The clinical-stage biopharmaceutical company, which is focused on the cancer immunotherapy field, is developing POLB 001 as a potentially preventative oral therapy.
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical, has raised £3.5 million before expenses through a share placing. Cathal Friel, executive chair, subscribed for £250,000 of the placing.
Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial
Cavendish has reiterated its 'buy' rating on Poolbeg Pharma PLC (AIM:POLB), arguing that the drug developer's first patient dosing marks the start of a value-creating period for the shares. The broker set a target price of 19p, implying upside of about 170% from the current 7.4p (up 5% on the day).
Poolbeg doses first patient in cancer immunotherapy safety trial
Poolbeg Pharma PLC (AIM:POLB), a clinical-stage biopharmaceutical company focused on cancer immunotherapy, has dosed the first patient in its POLB 001 TOPICAL clinical trial. The AIM-listed company is testing POLB 001 as a preventative treatment for cytokine release syndrome, a potentially serious immune reaction, in patients with relapsed or refractory multiple myeloma.
Poolbeg Pharma secures South African patent for lead drug candidate
Poolbeg Pharma PLC (AIM:POLB), the biopharmaceutical company focused on cancer immunotherapy, said it had been granted a patent in South Africa for its lead drug candidate, POLB 001. The patent covers the use of POLB 001 in preventing severe influenza and hypercytokinaemia, an excessive immune response also known as a cytokine storm, and runs until December 2038.
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.
European patent boosts Poolbeg Pharma's POLB 001 IP portfolio
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical company, has been granted a European patent for its POLB 001 treatment in cancer immunotherapy-induced cytokine release syndrome (CRS). The decision comes from the European Patent Office and covers protection across EPO member states.
Similar companies
-
Paradigm Biopharmaceuticals Limited
PBIGF
·
Other OTC
Compare
-
Kintor Pharmaceutical Limited
KNTPF
·
Other OTC
Compare
-
VitaSpring Biomedical Co. Ltd.
VSBC
·
Other OTC
Compare
-
Imugene Limited
IUGNF
·
Other OTC
Compare
-
Shield Therapeutics plc
SHIEF
·
Other OTC
Compare
-
Senzime AB (publ)
SNZZF
·
Other OTC
Compare